Cite
Evaluation of the respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays.
MLA
Quinton, Mikayla, et al. “Evaluation of the Respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex Assays.” Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology, vol. 150–151, June 2022, p. 105164. EBSCOhost, https://doi.org/10.1016/j.jcv.2022.105164.
APA
Quinton, M., Geahr, M., Gluck, L., Jarrett, J., & Mostafa, H. H. (2022). Evaluation of the respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays. Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology, 150–151, 105164. https://doi.org/10.1016/j.jcv.2022.105164
Chicago
Quinton, Mikayla, Melissa Geahr, Linda Gluck, Junko Jarrett, and Heba H Mostafa. 2022. “Evaluation of the Respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex Assays.” Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology 150–151 (June): 105164. doi:10.1016/j.jcv.2022.105164.